Use of compound or pharmaceutically acceptable salt thereof in treatment of lipid metabolic diseases
Drugs prepared from compounds or their pharmaceutically acceptable salts address the issue of high-frequency injections in existing drugs for treating lipid metabolism disorders, achieving longer duration of medication and better adherence, adapting to different patient responses, and providing safe and effective long-term efficacy.
Patent Information
- Application Number
- PCT/CN2025/131650
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-11-01
- Filing Date
- 2025-10-31
- Publication Date
- 2026-05-07
AI Technical Summary
Existing drugs for treating lipid metabolism disorders require frequent injections, leading to poor patient compliance, numerous side effects, and significant differences in drug response among different patients. The long-term efficacy and safety require further verification.
Provide a compound or a pharmaceutically acceptable salt thereof for use in the preparation of a drug for lowering triglycerides, total cholesterol, low-density lipoprotein and other related diseases, administered once every 1-30 days at a dose of up to 0.2 mg/kg, for example from 0.8 ng/kg to 200 ng/kg, via a non-enteric route such as intravenous or intramuscular administration.
Compounds or their pharmaceutically acceptable salts have a longer duration of action, reduce the frequency of dosing, improve patient compliance, reduce side effects, adapt to different patient responses, and provide safer and more effective long-term efficacy.